Hypertension and Drug Dose Monitoring - Business Plan

523 views

Published on

This is our final presentation of Summer School at High Tech Campus, Eindhoven, about our product DrugArt's business plan. We won the Best Entrepreneurial Team, at EIT ICT Labs Summer School, Wellbeing Innovation Camp 2013.

Published in: Business, Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
523
On SlideShare
0
From Embeds
0
Number of Embeds
68
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Hypertension and Drug Dose Monitoring - Business Plan

  1. 1. EITeam4 Hypertension & Drug Dose Monitoring
  2. 2. 1.000.000.000 Hypertension Patients 350.000.000 Overdosed 9.400.000 Deaths 10.000.000.000 € Annual Savings Problems
  3. 3. Patients Doctors Pharma Companies Insurance Companies Decision Makers
  4. 4. Over Dosage Timing of Dosage Reliable & 24/7 Monitoring Reliability of Intake It may be possible to reduce the number and dosage of drugs. “ ESH/ESC Guidelines for the management of arterial hypertension, 2013 10 Billion ProblemsMarket(€) Decision Makers Targeted Problems Ineffectivity of Drugs
  5. 5. Over Dosage Timing of Dosage Reliability of Intake Reliable & 24/7 Monitoring 10 Billion 70 Million ProblemsMarket(€) Targeted Problems Decision Makers Ineffectivity of Drugs
  6. 6. Over Dosage Timing of Dosage Reliability of Intake “ The importance of adequate BP control over the entire 24-hour period. Journal of Managed Care Pharmacy, William B. White 2007 Reliable & 24/7 Monitoring 10 Billion 70 Million 1.5 Billion ProblemsMarket(€) Targeted Problems Decision Makers Ineffectivity of Drugs
  7. 7. Over Dosage Timing of Dosage Reliability of Intake More than 50% of all medicines are prescribed, dispensed or sold inappropriately May 2010, WHO “ 10 Billion 70 Million 1.5 Billion 5 Billion Reliable & 24/7 Monitoring ProblemsMarket(€) Targeted Problems Decision Makers Ineffectivity of Drugs
  8. 8. Over Dosage Timing of Dosage Ineffectivity of Drugs Reliability of Intake Half of all patients fail to take medicines correctly. May 2010, WHO “ 10 Billion 70 Million 1.5 Billion 5 Billion 2 Billion Reliable & 24/7 Monitoring ProblemsMarket(€) Targeted Problems Decision Makers
  9. 9. Clinical Platform 1 2 Optimal Dose Intake Monitoring Blood Pressure Heart Beat Rate Drug Dose Info Physical Exercise Value Proposition
  10. 10. Strategy
  11. 11. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy
  12. 12. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy Insurance Companies (Joint Insurance) Allianz Aetna AXA PPP
  13. 13. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy Pharma Companies Bayer Teva Novartis Merck & Co. Insurance Companies (Joint Insurance) Allianz Aetna AXA PPP
  14. 14. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy Pharma Companies Bayer Teva Novartis Merck & Co. Insurance Companies (Joint Insurance) Allianz Aetna AXA PPP GP End User Prevention
  15. 15. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention Revenue Streams Worldwide
  16. 16. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention 1 Revenue Streams Worldwide
  17. 17. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention 1 Revenue Streams 2 Worldwide
  18. 18. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention 1 3 Revenue Streams 2 Worldwide
  19. 19. Go to India
  20. 20. 1.2 billion population Go to India
  21. 21. 1.2 billion population 40 million potential customers Go to India
  22. 22. 1.2 billion population 40 million potential customers 10% penetration in 10 years Go to India
  23. 23. 1.2 billion population 40 million potential customers 10% penetration in 10 years Go to India Hypertension is a well-known chronic disease
  24. 24. Clinics End User Care GP Pharma Companies Cardiologists 1 3 Go to India 2
  25. 25. -30 65 160 255 350 Roadmap & Financials 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Operating Profit Cumulative Operating Profit million € 0 Cumulative Operating Profit with Pharmas ROI
  26. 26. Risk Analysis 0 25 50 75 100 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Technical Value Proposition Competition Go 2 Market
  27. 27. Costs 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 R&D 3000000 2000000 1000000 1000000 500000 500000 250000 250000 250000 250000 250000 Patenting 100000 100000 100000 0 0 0 0 0 0 0 0 Marketing & Market research 2000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 Platform running cost 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 Salaries 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 Logistics 50000 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000 Misc Market Penetration Cost 5000000 10000000 10000000 10000000 25000000 25000000 10000000 10000000 10000000 10000000 10000000 Cost Breakdown
  28. 28. Nurse Visiting Hospital Visiting Clinical Cost Data Security Privacy Drug Coverage Side Effects Connection Report Life Style Service Cost Our Product Proteus Traditional high low Competition

×